Endothelial FOS expression and pre-eclampsia

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 119, Issue 13, 2012, Pages 1564-1571

  MacKenzie, R M ^a   Sandrim, V C ^b   Carty, D M ^a   McClure, J D ^a   Freeman, D J ^a   Dominiczak, A F ^a   McBride, M W ^a   Delles, C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Núcleo de Pós Graduação e Pesquisa Santa Casa de Belo Horizonte   (Brazil)

Author keywords

c Fos gene; endothelial cells; pre eclampsia; transcription factors

Indexed keywords

MESSENGER RNA; PROTEIN FOS;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PARITY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UMBILICAL VEIN ENDOTHELIAL CELL;

CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENES, FOS; GENETIC MARKERS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LONGITUDINAL STUDIES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, SECOND; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84869821126     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12016     Document Type: Article

References (32)

1. Hladunewich M, Karumanchi SA, Lafayette R,. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007; 2: 543-9.
2. Kovacs KJ,. c-Fos as a transcription factor: a stressful (re)view from a functional map. Neurochem Int 1998; 33: 287-97. (Pubitemid 28529506)
3. Piechaczyk M, Blanchard JM,. c-fos proto-oncogene regulation and function. Crit Rev Oncol Hematol 1994; 17: 93-131. (Pubitemid 24283869)
4. Poston L,. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep 2006; 58 (Suppl): 69-74.
5. McCarthy AL, Woolfson RG, Raju SK, Poston L,. Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Am J Obstet Gynecol 1993; 168: 1323-30. (Pubitemid 23122189)
6. Cockell AP, Poston L,. Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension 1997; 30: 247-51. (Pubitemid 27329005)
7. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS,. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285: 1607-12. (Pubitemid 32240253)
8. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ,. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122: 478-87.
9. Khan F, Belch JJ, MacLeod M, Mires G,. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 2005; 46: 1123-8. (Pubitemid 41533014)
10. Myers J, Mires G, MacLeod M, Baker P,. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 2005; 45: 258-63. (Pubitemid 40179969)
11. Vanwijk MJ, Svedas E, Boer K, Nieuwland R, Vanbavel E, Kublickiene KR,. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol 2002; 187: 1686-93. (Pubitemid 36026708)
12. Faas MM, van Pampus MG, Anninga ZA, Salomons J, Westra IM, Donker RB, et al., Plasma from preeclamptic women activates endothelial cells via monocyte activation in vitro. J Reprod Immunol 2010; 1987: 28-38.
13. Faas MM, Donker RB, van Pampus MG, Huls AM, Salomons J, de Vos P, et al., Plasma of pregnant and preeclamptic women activates monocytes in vitro. Am J Obstet Gynecol 2008; 199: 84-8.
14. Donker RB, Asgeirsdottir SA, Gerbens F, van Pampus MG, Kallenberg CG, te Meerman GJ, et al., Plasma factors in severe early-onset preeclampsia do not substantially alter endothelial gene expression in vitro. J Soc Gynecol Investig 2005; 12: 98-106. (Pubitemid 40202844)
15. Carty DM, Siwy J, Brennand JE, Zurbig P, Mullen W, Franke J, et al., Urinary proteomics for prediction of preeclampsia. Hypertension 2011; 57: 561-9.
16. Duckitt K, Harrington D,. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330: 565.
17. Brown MA, Lindheimer MD, De Swiet M, Van Assche A, Moutquin JM,. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV. (Pubitemid 32672922)
18. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
19. Breitling R, Armengaud P, Amtmann A, Herzyk P,. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004; 573: 83-92. (Pubitemid 39141040)
20. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 1995; 57: 289-300.
21. Marconcini L, Marchio S, Morbidelli L, Cartocci E, Albini A, Ziche M, et al., c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci USA 1999; 96: 9671-6. (Pubitemid 29398790)
22. Shaulian E, Karin M,. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-6. (Pubitemid 34521026)
23. Reynolds LP, Redmer DA,. Angiogenesis in the placenta. Biol Reprod 2001; 64: 1033-40. (Pubitemid 32239172)
24. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al., First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-5. (Pubitemid 38269892)
25. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al., Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58. (Pubitemid 36278583)
26. Carty DM, Anderson LA, Freeman DJ, Welsh PI, Brennand JE, Dominiczak AF, et al., Early pregnancy soluble E-selectin concentrations and risk of preeclampsia. J Hypertens 2012; 30: 954-9.
27. Marzioni D, Todros T, Cardaropoli S, Rolfo A, Lorenzi T, Ciarmela P, et al., Activating protein-1 family of transcription factors in the human placenta complicated by preeclampsia with and without fetal growth restriction. Placenta 2010; 31: 919-27.
28. Faxen M, Nasiell J, Lunell NO, Blanck A,. Differences in mRNA expression of endothelin-1, c-fos and c-jun in placentas from normal pregnancies and pregnancies complicated with preeclampsia and/or intrauterine growth retardation. Gynecol Obstet Invest 1997; 44: 93-6. (Pubitemid 27387328)
29. Kang JH, Song H, Yoon JA, Park DY, Kim SH, Lee KJ, et al., Preeclampsia leads to dysregulation of various signaling pathways in placenta. J Hypertens 2011; 29: 928-36.
30. Winn VD, Gormley M, Fisher SJ,. The Impact of Preeclampsia on Gene Expression at the Maternal-Fetal Interface. Pregnancy Hypertens 2011; 1: 100-8.
31. Stewart FM, Freeman DJ, Ramsay JE, Greer IA, Caslake M, Ferrell WR,. Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function throughout pregnancy in lean and obese mothers. J Clin Endocrinol Metab 2007; 92: 969-75. (Pubitemid 46465671)
32. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al., Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 2010; 56: 741-9.